Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.

Fulvestrant, letrozole best first-line endocrine therapy for advanced breast cancer

22 Sep 2017

Fulvestrant and letrozole seem to be the optimal first-line endocrine therapy choices for hormone receptor-positive (HR+) and human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC), according to a network meta-analysis.

The meta-analysis included 27 articles of eight randomized controlled trials (RCTs) corresponding to 3,492 ABC patients. Six monotherapies were investigated: anastrozole, fulvestrant, tamoxifen, exemestane and lestrozole; doses of 250 and 500 mg were considered.

Letrozole yielded better objective response rate (ORR) than tamoxifen (odds ratio [OR], 0.59; 95 percent CI, 0.43 to 0.80) and fulvestrant (OR, 0.54; 0.34 to 0.85) at 250 mg. Exemestane also produced better ORR than fulvestrant (OR, 0.61; 0.37 to 0.97) and tamoxifen (OR, 0.67; 0.48 to 0.91) at 250 mg.

In terms of survival, only one study reported on progression-free survival (PFS) while most looked at time to progression (TTP).  In terms of TTP/PFS, tamoxifen was less effective than both anastrozole (hazard ratio [HR], 0.84; 0.72 to 0.99) and letrozole (HR, 0.70; 0.60 to 0.81).

In comparison, anastrozole (HR, 0.72; 0.56 to 0.93), exemestane (HR, 0.75; 0.57 to 0.97) and letrozole (HR, 0.60; 0.46 to 0.76) all had better TTP/PFS than fulvestrant.

Fulvestrant at 500 mg yielded better TTP/PFS than 250 mg of anastrozole (HR, 1.54; 1.09 to 2.11), exemestane (HR, 1.61; 1.08 to 2.25), tamoxifen (HR, 1.84; 1.24 to 2.55) and fulvestrant (HR, 2.17; 1.34 to 3.11). Only letrozole was not inferior to 500 mg fulvestrant.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.